Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling

Phytotherapy Research

Volumn 30, Issue 11, 2016, Pages 1833-1840

  Kim, Boram ^a   Jung, Narae ^a   Lee, Sanghun ^a   Sohng, Jae Kyung ^a   Jung, Hye Jin ^a  

^a SunMoon University   (South Korea)

Author keywords

apigenin; c Met; cancer stem cell; flavonoid; glioblastoma

Indexed keywords

APIGENIN; CD133 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; NARINGENIN; PROTEIN KINASE B; QUERCETIN; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; MET PROTEIN, HUMAN;

ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL GROWTH; CELL SELF-RENEWAL; CLONOGENESIS; DOWN REGULATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; PHENOTYPE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; U373MG CELL LINE; U87MG CELL LINE; BRAIN NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; PATHOLOGY; TUMOR CELL LINE;

APIGENIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GLIOBLASTOMA; HUMANS; NEOPLASTIC STEM CELLS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84979517094     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5689     Document Type: Article

References (34)

1. Alonso MM, Diez-Valle R, Manterola L, et al. 2011. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One 6: e26740.
2. Bae IH, Lee WS, Yun DH, Han YH, Lee JS. 2014. 3-Hydroxy-3′,4′-dimethoxyflavone suppresses Bcl-w-induced invasive potentials and stemness in glioblastoma multiforme. Biochem. Biophys. Res. Commun. 450: 704–710.
3. Bao S, Wu Q, McLendon RE, et al. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756–760.
4. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. 2003. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4: 915–925.
5. Cazarolli LH, Zanatta L, Alberton EH, et al. 2008. Flavonoids: prospective drug candidates. Mini Rev. Med. Chem. 8: 1429–1440.
6. Chakrabarti M, Ray SK. 2015. Synergistic anti-tumor actions of luteolin and silibinin prevented cell migration and invasion and induced apoptosis in glioblastoma SNB19 cells and glioblastoma stem cells. Brain Res. 1629: 85–93.
7. Cheng L, Wu Q, Guryanova OA, et al. 2011. Elevated invasive potential of glioblastoma stem cells. Biochem. Biophys. Res. Commun. 406: 643–648.
8. Cho DY, Lin SZ, Yang WK, et al. 2013. Targeting cancer stem cells for treatment of glioblastoma multiforme. Cell Transplant. 22: 731–739.
9. Feng X, Zhou Q, Liu C, Tao ML. 2012. Drug screening study using glioma stem-like cells. Mol. Med. Rep. 6: 1117–1120.
10. Galli R, Binda E, Orfanelli U, et al. 2004. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64: 7011–7021.
11. Harborne JB. 1986. Nature, distribution and function of plant flavonoids. Prog. Clin. Biol. Res. 213: 15–24.
12. Havsteen BH. 2002. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 96: 67–202.
13. Hothi P, Martins TJ, Chen L, et al. 2012. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget 3: 1124–1136.
14. Joo KM, Jin J, Kim E, et al. 2012. MET signaling regulates glioblastoma stem cells. Cancer Res. 72: 3828–3838.
15. Kim Y, Joo KM, Jin J, Nam DH. 2009. Cancer stem cells and their mechanism of chemo-radiation resistance. Int J Stem Cells 2: 109–114.
16. Kong DS, Song SY, Kim DH, et al. 2009. Prognostic significance of c-Met expression in glioblastomas. Cancer 115: 140–148.
17. Lee J, Kotliarova S, Kotliarov Y, et al. 2006. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391–403.
18. Li Y, Li A, Glas M, et al. 2011. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc. Natl. Acad. Sci. U. S. A. 108: 9951–9956.
19. Liu G, Yuan X, Zeng Z, et al. 2006. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5: 67.
20. Liu J, Cao XC, Xiao Q, Quan MF. 2015. Apigenin inhibits HeLa sphere-forming cells through inactivation of casein kinase 2α. Mol. Med. Rep. 11: 665–669.
21. Lou C, Zhang F, Yang M, et al. 2012. Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells. PLoS One 7: e50956.
22. Louis DN, Ohgaki H, Wiestler OD, et al. 2007. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114: 97–109.
23. Nabeshima K, Shimao Y, Sato S, et al. 1997. Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology 31: 436–443.
24. Sak K, Everaus H. 2015. Role of flavonoids in future anticancer therapy by eliminating the cancer stem cells. Curr. Stem Cell Res. Ther. 10: 271–282.
25. Singh SK, Hawkins C, Clarke ID, et al. 2004. Identification of human brain tumour initiating cells. Nature 432: 396–401.
26. Stupp R, Mason WP, van den Bent MJ, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352: 987–996.
27. Sundar SJ, Hsieh JK, Manjila S, Lathia JD, Sloan A. 2014. The role of cancer stem cells in glioblastoma. Neurosurg. Focus 37: E6.
28. Tang AQ, Cao XC, Tian L, He L, Liu F. 2015. Apigenin inhibits the self-renewal capacity of human ovarian cancer SKOV3‑derived sphere-forming cells. Mol. Med. Rep. 11: 2221–2226.
29. Trusolino L, Bertotti A, Comoglio PM. 2010. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11: 834–848.
30. Visnyei K, Onodera H, Damoiseaux R, et al. 2011. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol. Cancer Ther. 10: 1818–1828.
31. Wen PY, Kesari S. 2008. Malignant gliomas in adults. N. Engl. J. Med. 359: 492–507.
32. Yu SP, Yang XJ, Zhang B, et al. 2011. Enhanced invasion in vitro and the distribution patterns in vivo of CD133+ glioma stem cells. Chin Med J (Engl) 124: 2599–2604.
33. Zhang X, Zhang W, Mao XG, Zhen HN, Cao WD, Hu SJ. 2013. Targeting role of glioma stem cells for glioblastoma multiforme. Curr. Med. Chem. 20: 1974–1984.
34. Zhang Y, Wang SX, Ma JW, et al. 2015. EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. J. Neurooncol 121: 41–52.